Company Filing History:
Years Active: 2011-2015
Title: Thomas Koenig: Innovator in Breast Cancer Prognosis
Introduction
Thomas Koenig is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of cancer research, particularly in the prognosis of breast cancer. With a total of 3 patents to his name, his work focuses on innovative methods for predicting disease outcomes.
Latest Patents
Koenig's latest patents include groundbreaking inventions aimed at improving breast cancer prognosis. One of his notable patents is titled "Methods for the prognosis of breast cancer." This invention relates to modified and genomic sequences, as well as oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA. It also includes a method for predicting disease-free survival and response to endocrine treatment in subjects with cell proliferative disorders of breast tissues. Another significant patent is "Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy." This invention similarly focuses on genomic sequences and oligonucleotides for detecting cytosine methylation, aiding in predicting responses to treatment.
Career Highlights
Thomas Koenig is associated with Epigenomics AG, a company dedicated to developing innovative cancer diagnostics. His work at Epigenomics AG has positioned him as a key player in the field of epigenetics and cancer research. His inventions have the potential to significantly impact patient care and treatment strategies.
Collaborations
Throughout his career, Koenig has collaborated with esteemed colleagues such as John Foekens and Nadia Harbeck. These collaborations have further enhanced the quality and reach of his research, contributing to advancements in breast cancer prognosis.
Conclusion
In summary, Thomas Koenig is a dedicated inventor whose work in breast cancer prognosis is paving the way for improved diagnostic methods. His innovative patents and collaborations reflect his commitment to advancing cancer research and patient care.